company background image
0T20 logo

Traws Pharma DB:0T20 Stock Report

Last Price

€6.60

Market Cap

€13.9m

7D

0%

1Y

-57.1%

Updated

02 Nov, 2024

Data

Company Financials +

0T20 Stock Overview

A clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer.

0T20 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Traws Pharma, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Traws Pharma
Historical stock prices
Current Share PriceUS$6.60
52 Week HighUS$29.75
52 Week LowUS$6.60
Beta1.38
11 Month Change0%
3 Month Change-20.96%
1 Year Change-57.07%
33 Year Change-91.43%
5 Year Change-95.60%
Change since IPO-99.58%

Recent News & Updates

Recent updates

Shareholder Returns

0T20DE PharmaceuticalsDE Market
7D0%-1.7%-1.8%
1Y-57.1%-12.7%13.2%

Return vs Industry: 0T20 underperformed the German Pharmaceuticals industry which returned -12.7% over the past year.

Return vs Market: 0T20 underperformed the German Market which returned 13.2% over the past year.

Price Volatility

Is 0T20's price volatile compared to industry and market?
0T20 volatility
0T20 Average Weekly Movement8.8%
Pharmaceuticals Industry Average Movement7.8%
Market Average Movement5.0%
10% most volatile stocks in DE Market11.5%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 0T20's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 0T20's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
199818Werner Cautreelswww.trawspharma.com

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers.

Traws Pharma, Inc. Fundamentals Summary

How do Traws Pharma's earnings and revenue compare to its market cap?
0T20 fundamental statistics
Market cap€13.93m
Earnings (TTM)-€126.47m
Revenue (TTM)€208.55k

66.8x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0T20 income statement (TTM)
RevenueUS$226.00k
Cost of RevenueUS$0
Gross ProfitUS$226.00k
Other ExpensesUS$137.28m
Earnings-US$137.05m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-45.30
Gross Margin100.00%
Net Profit Margin-60,641.15%
Debt/Equity Ratio0%

How did 0T20 perform over the long term?

See historical performance and comparison